The role of overweight and obesity in selected gynecological malignancies

A review of literature data related to the effects of overweight and obesity on the development and course of selected gynecological malignancies: endometrial, breast and ovarian cancer is presented. Three hypotheses are included in an attempt to explain this relationship: the adipokinine hypothesis, a hypothesis involving the effects of excessive estrogen levels, and the insulin hypothesis.

Obesity; Endometrial cancer; Breast cancer; Ovarian cancer.

[1] Arnold M., Pandeya M., Byrnes G., Renehan A.G., Stevens G.A., Ezzati M., et al.: “Global burden of cancer attributable to high body-mass index in 2012: a population-based study”. Lancet Oncol., 2015, 16, 36.

[2] Anderson A.S., Key T.J., Norat T., Scoccianti C., Cecchini M., Berrino F., et al.: “European code against cancer 4th edition: Obesity, body fatness and cancer”. Cancer Epidemiol., 2015, 39, S3.

[3] Report of a WHO Expert Committee: “Physical status: the use and interpretation of anthropometry”. WHO Technical Report Series No.854, 1995. Available at: http://apps.who.int/iris/bitstream/10665/ 37003/1/WHO_TRS_854.pdf

[4] Bergström A., Pisani P., Tenet V., Wolk A., Adami H.O.: “Overweight as an avoidable cause of cancer in Europe”. Int. J. Cancer, 2001, 91, 421.

[5] Mazzarella L.: ”Why does obesity promote cancer? Epidemiology, biology, and open questions”. Ecancer, 2015, 9, 554.

[6] Renehan A.G., Soerjomataram I., Leitzmann MF.: “Interpreting the epidemiological evidence linking obesity and cancer. A framework for population-attributable risk estimations in Europe”. Eur. J. Cancer, 2010, 46, 2581.

[7] Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J.: “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults”. N. Engl. J. Med., 2003, 348, 1625.

[8] Felix A.S., Scott McMeekin D.S., Mutch D., Walker J.L., Creasman W.T., Cohn D.E., et al.: “Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/ Gynecologic Oncology Group 210 trial”. Gynecol. Oncol., 2015, 139, 70.

[9] Sethi J.K., Vidal-Puig A.J.: “Adipose tissue function and plasticity orchestrate nutritional adaptation”. J. Lipid. Res., 2007, 48, 1253.

[10] Ouchi N., Parter J.L., Lugus J.J., Walsh K.: “Adipokines in inflammation and metabolic disease”. Nat. Rev. Immunol., 2011, 11, 85.

[11] Mirza R.E., Koh T.J.: “Contributions of cell subsets to cytokine production during normal and impaired wound healing”. Cytokine, 2015, 71, 409.

[12] Nieman K.M., Romero I.L., Van Houten B., Lengyel E.: “Adipose tissue and adipocytes support tumorigenesis and metastasis”. Biochem. Biopchys. Acta, 2013, 183, 1533.

[13] Taniguchi K., Karin M.: “IL-6 and related cytokines as the critical lynchpins between inflammation and cancer”. Semin. Immunol., 2014, 26, 54.

[14] Chin Y.R., Toker A.: “Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer”. Cell Signal., 2009, 21, 470.

[15] Maki R.G.: “Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer”. J. Clin. Oncol., 2010, 28, 4985.

[16] Cohen D.H., LeRoith D.: “Obesity, type 2 diabetes, and cancer: the insulin and IGF connection”. Endocr. Relat. Cancer, 2012, 19, F27.

[17] Kurman R.J., Kaminski P.F., Norris H.J.: “The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients”. Cancer, 1985, 56, 403.

[18] Iyengar N.M., Hudis C.A., Dannenberg A.J.: „Obesity and cancer: local and systemic mechanisms”. Ann. Rev. Med., 2015, 66, 297.

[19] Kreizman-Shefel H., Pricop J., Goldman S., Elmalah I., Shalev E.: “Distribution of estrogen and progesterone receptors isoforms in endometrial cancer”. Diagn Pathol., 2014, 9, 77.

[20] International Agency for Resaerch on Cancer (IARC): “Globocan 2012 Cancer Incidence, Mortality and Prevelence Worldwide in 2012”, Available at: http://globocan.iarc.fr

[21] Wojciechowska U., Didkowska J., Zatoński W.: „Zachorowania i zgony na nowotwory złośliwe w Polsce w 2012 roku. Warszawa: Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie”, 2014, 40, 49.

[22] Colombo N., Preti E., Landoni S., Carinelli S., Colombo A., Marini A., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 24, vi33.

[23] Ali A.T.: “Reproductive factors and the risk of endometrial cancer”. Int J. Gynecol. Cancer, 2014, 24, 384.

[24] Luo J., Beresford A.S., Chen C., Chlebowski R.T., Garcia L., Kuller L.H., et al.: “Association between diabetes, diabetes treatment and risk of developing endometrial cancer”. Br. J. Cancer, 2014, 111, 1432.

[25] Schouten L.J., Goldbohm R.A., van den Brandt P.A.: “Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study”. J. Natl. Cancer Inst., 2004, 96, 1635.

[26] Smits A., Lopes A., Das N., Bekkers R., Massuger L., Galaal K.: “The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter?”. Gynecol. Oncol., 2014, 132, 137.

[27] Setiawan V.W., Yang H.P., Pike M.C., McCann E.S., Yu H., Xiang Y.B. et al.: “Type I and II endometrial cancers: have they different risk factors?” J. Clin. Oncol., 2013, 31, 2607.

[28] Arem H., Chlebowski R., Stefanick ML., Anderson G., Wactawski- Wende J., Sims S., et al.: “Body mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative”. Gynecol Oncol., 2013, 128, 181.

[29] Ballard-Barbash R., Friedenreich CM., Courneya KS., Siddiqi S.M., McTiernan A., Alfano C.M.: “Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review”. J. Natl. Cancer Inst., 2012, 104, 815.

[30] Nevadunsky N.S., Van Arsdale A., Strickler H.D.: “Metformin use and endometrial cancer survival”. Gynecol. Oncol., 2014, 132, 236.

[31] Strong M.L., Ohlstein J.F., Biagas B.A., Rhodes L.V., Pei D.T., Tucker H.A., et al.: “Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers”. Breast Cancer Res., 2015, 17, 112 .

[32] Protani M., Coory M., Martin J.H.: “Effect of obesity on survival of women with breast cancer: systemic review and meta-analysis”. Breast Cancer Res Treat., 2010, 123, 627.

[33] Brown K.A., Simpson E.R.: “Estrogens, Obesity, Inflammation and breast cancer – what is the link?” Semin. Reprod. Med., 2015, 33, 208.

[34] Coughlin S.S., Smith S.A.: “The insulin-like growth factor axis, adipokines, physical activity and obesity in relation to breast cancer incidence and recurrence”. Cancer Clin. Oncol., 2015, 4, 24.

[35] Niraula S., Ocena A., Ennis M., Googwin P.J.: “Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis” Breast Cancer Res. Treat., 2012, 134, 769.

[36] Chan D., Norat T.: “Obesity and breasta cancer:not only a risk factor of the disease”. Curr. Treat. Options Oncol., 2015, 16, 22.

[37] Neilson H.K., Conroy S.M., Friedenreich C.M.: “The influence of energetic factors on biomarkers of postmenopausal breast cancer risk”. Curr. Nutr. Rep., 2014, 3, 22 .

[38] Chan D.S.M, Vieira A.R., Aune D., Bandera E.V., Greenwood., Mc- Tienan A., et al.: “Body mass index and survival in women with breast cancer – systemic literature review and meta-analysis of 82 followup studies”. Ann. Oncol., 2014, 25, 1901.

[39] Scholz C., Andergassen U., Hepp P., Schindlbeck C., Friedl T.W., Harbeck N., et al.: “Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer”. Breast Cancer Res. Treat., 2015, 151, 569.

[40] Chlebowski R.T., Blackburn G.I., Thomson C.A., Nixon D.W., Shapiro A., Hoy M.K., et al.: “Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study”. J. Natl. Cancer Inst., 2006, 98, 1767.

[41] VanMieghem T., Leunen K., Pochet N., De Moor B., De Smet F., Amant F., et al.: “Body mass index and HER-2 overexpression in breat cancer patients ovet 50 years of age”. Breast Cancer Res. Treat., 2007, 106, 127.

[42] Adamo V., Ricciardi G.R., Adamo B., Ferraro G., Franchina T., Rossello R., et al.: “The risk of toxicities from trastuzumab alone or in combination in an elderly breast cancer population”. Oncology, 2014, 86, 16.

[43] Hao S., Liu Y., Yu K.D., Chen S., Yang W.T., Shao Z.M.: “Overweight as a prognostic factor for triple negative breast cancers in Chinese women”. Plos One, 2015, 10, 1.

[44] Turkoz F.P., Solak M., Petekkaya I., Keskin O., Kertmen N., Sarici F., et al.: “The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women”. J. BUON., 2013, 18, 335.

[45] Ademuyiwa F.O., Groman A., O’Connor T., Ambrosone C., Watroba N., Edge S.B.: “Impact of body mass index on clinical outcomes in triple-negative breast cancer”. Cancer, 2011, 117, 4132.

[46] Protani M., Coory M., Martin J.H.: “Effect of obesity on survival of women with breast cacncer: systemic review and meta-analysis”. Breast Cancer Res. Treat., 2010, 123, 627.

[47] Griggs J.J., Sorbero M.E., Lyman G.H.: “Undertreatment of obese women receiving breast cancer chemotherapy”. Arch. Intern. Med., 2005, 165, 1267.

[48] Pfeiler G., Stoger H., Dubsky P., Mlineritsch B., Singer C., Balic M., Fitzal F., et al.: “Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone-receptor positive breast cancer: an analysis of 1509 patients of ABCSG-06 tral”. Br. J. Cancer, 2013, 108, 1408.

[49] Folkerd E.J., Dixon J.M., Renshaw L., A'Hern R.P., Dowsett M.: “Suppresion of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer”. J. Clin. Oncol., 2012, 30, 2977 – 80

[50] Ewertz M., Gray K.P., Regan M.M., Ejlertsen B., Price K.N., Thürlimann B., et al.: “Obesity and risk of reccurence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the brest international group 1-98 trial”. J. Clin. Oncol., 2012, 30, 3967.

[51] Niravath P.: “Aromatase inhibitor-induced arthralgia: a review”. Ann. Oncol., 2013, 24, 1443.

[52] Somastander P., McFadden D.W., Hileman S.M., Vona-Davis L.: “Leptin is a growth factor in a cancer”. J. Surg. Res., 2004, 116, 337.

[53] Yim M., Zhou J., Gorak E.J., Quddus F.: “Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systemic review and meta-analysis”. Oncologist, 2013, 18, 1248.

[54] Carpenter C.L., Duvall K., Jardack P.: “Weight loss reduces breast ductal fluid estrogens in obese postmenopausal women: a single arm intervention pilot study”. Nutr. J., 2012, 11, 102.

[55] Seidman J.D., Horkayne-Szakaly I., Cosin J.A., Ryu H.S., Haiba M., Boice C.R., et al.: ”Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum”. Gynecol. Oncol., 2006, 103, 703.

[56] Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., et al.: “Grading ovarian serous carcinoma using a twotier system”. Am. J. Surg. Pathol., 2004, 28, 496.

[57] Kurman R.J., Shih I.M.: “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory”. Am. J. Surg. Pathol., 2010, 34, 433.

[58] Gershenson D.M., Sun C.C., Lu K.H., Coleman R.L., Sood A.K., Malpica A., et al.: “Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary”. Obstet. Gynecol., 2006, 108, 361.

[59] Plaxe S.C.: “Epidemiology of low-grade serous ovarian cancer”. Am. J. Obstet. Gynecol., 2008, 198, 459.e1.

[60] Schmeler K.M., Sun C.C., Bodurka D.C.: “Neoadjuvant chemotherapy for low- grade serous carcinoma of the ovary or peritoneum”. Gynecol. Oncol., 2008, 108, 510.

[61] Permuth-Wey J., Sellers T.: “Epidemiology of ovarian cancer”. Methods Mol. Biol., 2009, 472, 413.

[62] Matthews K.S., Straughn J.M. Jr, Kemper M.K., Hoskins K.E., Wang W., Rocconi R.P.: “The effect of obesity on survival in patients with ovarian cancer”. Gynecol Oncol., 2009, 112, 389.

[63] Schouten L.J., Rivera C., Hunter D.J., Spiegelman D., Adami H.O., Arslan A., et al.: “Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies”. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 902.

[64] Engeland A., Tretli S., Hansen S., Bjørge T: “Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women”. Am. J. Epidemiol., 2007, 165, 44.

[65] Farrow D.C., Weiss N.S., Lyon J.L., Daling J.R.: “Association of obesity and ovarian cancer in a case-control study”. Am. J. Epidemiol., 1989, 129, 1300.

[66] Olsen C.M., Nagle C..M, Whiteman D.C., Ness R., Pearce C.L., Pike M.C., et al.: “Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Associatio Consortium”. Endocr. Relat. Cancer, 2013, 20, 251.

[67]Previs R.A., Kilgore J., Craven R., Broadwater G., Bean S., Wobker S., et al.: “Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2014, 24, 670.

[68] Nagle C.M., Dixon S.C., Jensen A., Kjaer S.K., Modugno F., deFazio A., et al.: “Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium”. Br. J. Cancer, 2015, 113, 817.